Skip to main content
Figure 1 | BMC Infectious Diseases

Figure 1

From: Plasma levels of soluble urokinase-type plasminogen activator receptor (suPAR) and early mortality risk among patients enrolling for antiretroviral treatment in South Africa

Figure 1

Log10 suPAR concentrations among patients (n = 293) enrolling in an antiretroviral treatment (ART) programme. Individual data points represent individual patients who were either receiving ART and alive after completing 4 months of treatment (n = 218), had died before starting ART or during the first 16 weeks of treatment (n = 39), or were lost to the programme (n = 36). Group median values are shown by a bar.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us